Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.

  • End date
    Feb 1, 2023
  • participants needed
  • sponsor
    Zensun Sci. & Tech. Co., Ltd.
Updated on 4 March 2022
ejection fraction
systolic heart failure


The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.


The mortality of chronic heart failure patients remains high, in spite of current treatment. RhNRG-1(recombinant human neuregulin-1)directly work on the cardiomyocyte and restored the normal structure and function of it. Both the preclinical trials, phase II clinical trials and already completed phase III clinical trails have confirmed that rhNRG-1 effectively enhance the heart function, reverse the remodeling of left ventricular, and reduce all-cause mortality in heart failure animals and humans. More importantly, rhNRG-1 can significantly reduce the mortality of heart failure subjects with baseline NT-proBNP level 1600 fmol/mL and NYHA class II to III. In this phase III study, the investigators will further confirm the efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.

Condition Chronic Heart Failure
Treatment Placebo, rhNRG-1
Clinical Study IdentifierNCT03388593
SponsorZensun Sci. & Tech. Co., Ltd.
Last Modified on4 March 2022


Yes No Not Sure

Inclusion Criteria

\. Age between 18 and 75, gender balance (no more than 960 subjects of either gender in total 1600 subjects)
\. Left ventricular ejection fraction (LVEF)40% (ECHO)
\. Subjects with chronic heart failure (NYHA class II OR III )
\. 600 pg/ml NT-proBNP1700 pg/ml ( by Roche assay Kit in central lab)
\. Diagnosed as chronic systolic heart failure (history, symptoms, signs), and in stable condition in the last one month
\. Receiving standard therapy for chronic heart failure, reach target dose or max tolerable dose for one month, or has not changed the dose for one month before randomization
\. Capable of signing the informed consent form

Exclusion Criteria

\. New chronic heart failure patients, or patients receiving standard therapy on chronic heart failure for less than 3 months
\. NYHA functional class I OR IV
\. NT-proBNP < 600 pg/ml OR NT-proBNP>1700 pg/ml (by Roche assay Kit in central lab)
\. Patients with hypertrophic cardiomyopathy, rheumatic heart disease, constrictive pericarditis, significant valvular pathological change or congenital heart diseases, primary or secondary severe pulmonary artery hypertension
\. Ischemic heart failure without recanalization or with recanalization in recent six months
\. Acute MI in the last 3 months
\. Unstable angina
\. Patients with acute pulmonary edema or acute hemodynamic disorder
\. Chronic heart failure patients with acute hemodynamic disorder or acute decompensation in the last 1 month (symptoms and signs suggest worsening chronic heart failure and may require intravenous drug therapy)
\. Patients with right heart failure caused by pulmonary disease
\. Patients diagnosed with pericardial effusion (>50 ml) or pleural effusion(>200 ml), or evidenced by Echocardiogram
\. Cardiac surgery or cerebrovascular accident within recent six months
\. Preparing for heart transplantation or CRT, or has received CRT
\. Serious ventricular arrhythmia (sustained ventricular tachycardia or frequent paroxysmal ventricular tachycardia)
Diagnosis of perinatal or chemotherapy-induced cardiomyopathy in last 12 months
\. Serious hepatic or renal dysfunction (bilirubin 1.5 times above the normal upper limit, AST or ALT 2 times above the normal upper limit, serum creatinine>2.0mg/dL, HBV or HCV positive)
\. Serum potassium <3.2 mmol/L or >5.5 mmol/L
\. Systolic blood pressure <90mmHg or >160mmHg
\. Women of childbearing age who have a pregnancy plan within 2 years (women of childbearing age are defined as women who have a pregnancy physiology)
\. Pregnant or lactating women
\. Patients who participated in any clinical trial in the recent three months
\. Subject with a life expectancy less than 6 months as assessed by the investigator
\. Serious nervous system diseases (Alzheimer's disease, advanced Parkinsonism),lower limb defects, or deaf-mute
\. History of any malignancy or suffering from cancer, or biopsy proven pre-malignant condition (e.g., DICS or cervical atypia)
\. Evidence (physical examination, chest X-ray (CXR), ECHO or other tests) shows some active malignancy or adenoidal hypertrophy or neoplasm that has an effect on heart function or the endocrine system, e.g., pheochromocytoma or hyperthyroidism (Thyroid nodules with normal thyroid function do not need to be excluded)
\. As judged by the investigator that the subject cannot complete the study or adhere to the study requirements (due to the management reasons or others)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note